Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017

Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline

TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral Presentation; TP-271 Phase 1 Single-Ascending Dose Data to be Featured in Poster Presentation

WATERTOWN, Mass., May 22, 2017 --  Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced upcoming data presentations at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting, taking place June 1-5, 2017 in New Orleans, LA.  In total, eleven presentations will be given including pharmacokinetic and global surveillance data for the Company's phase 3 antibiotic drug candidate, eravacycline, one oral presentation highlighting TP-6076 phase 1 single-ascending dose (SAD) study results, one poster presentation featuring TP-271 SAD study results, and additional pipeline program data.

“We continue to be pleased with the additional supportive data generated for eravacycline which shows consistent potency against drug-resistant bacteria in ongoing global surveillance studies,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We also have been highly encouraged by the preclinical profiles observed to date with both TP-271 and TP-6076, and we look forward to sharing the data from our first-in-human, phase 1 SAD studies for each of these promising candidates with the medical community at ASM Microbe this year.”

Details for the data presentations at ASM Microbe 2017 are as follows:

Eravacycline Data Presentations

Poster #54: Activity of Eravacycline Against Carbapenem Resistant Enterobacteriaceae and Acinetobacter baumannii
Date and time: Saturday, June 3 from 12:15 – 2:15 p.m. CT
Session info: Session 185 - AAID01 - Antibacterial Resistance: In vitro Activity and Resistance to Tigecycline, Fosfomycin and Derivatives

Poster #189: Pharmacokinetics-Pharmacodynamics (PK-PD) of Efficacy for Eravacycline Against Escherichia coli in an In Vitro Infection Model
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents

Poster #190: Compartmental Pharmacokinetics of Eravacycline following Intravenous Administration in Rabbits
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents

Poster #191: PK/PD of the Novel Fluorocycline Eravacycline is Efficacious in a Murine E. coli Thigh Model.
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents

Clinical Pipeline Data Presentations

Oral Presentation #8:  Safety, Tolerability and Pharmacokinetics of Single Doses of TP-6076, a Novel Fully Synthetic Tetracycline, in a Phase 1 Study
Date and time: Saturday, June 3 at 4:30 p.m. CT
Session info: Session 264 - Development of New Drugs and Strategies for Hospital-acquired Pneumonia Caused by MDR Pathogens, Room 215

Poster #198:  Safety, Tolerability and Pharmacokinetics of Single Intravenous Doses of TP-271, a Novel Fluorocycline Antibiotic
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents

Preclinical Pipeline Data Presentations

Poster #36: The Novel Fluorocycline TP-271 is Efficacious in a Nonhuman Primate Model of Inhalation Anthrax.
Date and time: Friday, June 2 from 12:45 – 2:45 p.m. CT
Session info: Session 035 - AAID - Respiratory Tract Infections: Clinical and Laboratory Studies

Poster #94: The Novel Fluorocycline TP-271 is Efficacious in a Murine A. baumannii Pneumonia Model.
Date and time: Friday, June 2 from 12:45 – 2:45 p.m. CT
Session info: Session 037 - AAID01 - Antibacterial Resistance: Laboratory Studies of Antimicrobial Resistance

Poster #332: TP-6076, A Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent against a Broad Range of Pathogens, including Carbapenem-resistant Enterobacteriaceae
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 351 - AAID11 - New Antimicrobial Agents: New Antibacterial Agents II

Multidrug-Resistant Infection Prevalence Data Presentations

Poster #95:  Prevalence of Multidrug-Resistant Acinetobacter baumannii (MDR AB) by ICU Status and Setting in USA Hospitals in 2015-2016: A Multicenter Study
Date and time: Saturday, June 3 from 12:15 – 2:15 p.m. CT
Session info: Session 187 - AAID01 - Antibacterial Resistance: Molecular Epidemiology of Non-fermentative Gram-negative bacilli

Poster #100:  Prevalence of Multidrug-Resistance (MDR) in Enterobacteriaceae (ENT) by ICU Status and Setting in USA Hospitals in 2015-2016: A Multicenter Study
Date and time: Sunday, June 4 from 12:15 – 2:15 p.m. CT
Session info: Session 338 - AAID01 - Antibacterial Resistance: Global Surveillance of Multi-Drug Resistant Bacteria

ASM Microbe 2017 is the integration of two of the American Society of Microbiology’s meetings:  the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). Full abstracts can be found on the ASM Microbe website at http://www.asmmicrobe.org/.

About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information. 

Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
[email protected]

Argot Partners
Maeve Conneighton
206.899.4940
[email protected]

Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]